US 11,859,017 B2
Immunotherapy against several tumors including lung cancer
Toni Weinschenk, Tuebingen (DE); Steffen Walter, Houston, TX (US); Jens Fritsche, Tuebingen (DE); Colette Song, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Mar. 18, 2022, as Appl. No. 17/698,531.
Application 17/698,531 is a continuation of application No. 17/691,576, filed on Mar. 10, 2022.
Application 17/691,576 is a continuation of application No. 17/525,023, filed on Nov. 12, 2021.
Application 17/525,023 is a continuation of application No. 17/238,932, filed on Apr. 23, 2021.
Application 17/238,932 is a continuation of application No. 16/599,198, filed on Oct. 11, 2019, granted, now 11,161,877, issued on Nov. 2, 2021.
Application 16/599,198 is a continuation of application No. 16/444,693, filed on Jun. 18, 2019, granted, now 10,479,818, issued on Nov. 19, 2019.
Application 16/444,693 is a continuation of application No. 15/639,165, filed on Jun. 30, 2017, abandoned.
Application 15/639,165 is a continuation of application No. 14/908,078, abandoned, previously published as PCT/EP2014/066755, filed on Aug. 4, 2014.
Claims priority of provisional application 61/862,213, filed on Aug. 5, 2013.
Claims priority of application No. 1313987 (GB), filed on Aug. 5, 2013; and application No. 1403297 (GB), filed on Feb. 25, 2014.
Prior Publication US 2022/0298207 A1, Sep. 22, 2022
Int. Cl. A61K 38/08 (2019.01); C07K 7/08 (2006.01); C12N 5/0783 (2010.01); C12N 9/64 (2006.01); A61K 38/17 (2006.01); C07K 7/06 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 14/7051 (2013.01); C12N 5/0638 (2013.01); C12N 9/6491 (2013.01); C12Y 304/24065 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C12N 2502/11 (2013.01)] 20 Claims
 
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that kill the cancer cells that present a peptide consisting of the amino acid sequence RVLPPSALQSV (SEQ ID NO: 87),
wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with a human class I or II MHC molecule on the surface of the antigen presenting cell,
wherein said cancer is selected from non-small cell lung cancer, gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, renal cancer, prostate cancer, melanoma, glioblastoma, and bladder cancer.